To the full analysis
Coloplast stock: growth
COLO-B.COColoplast reported $4.29B in revenue for fiscal 2026, up 3.8% on the prior year, up 8.3% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
7%
per year from 2007 to 2026, per share 7%
Earnings (Annual rate)
11.8%
per year from 2007 to 2026, per share 11.9%
Free cash flow (Annual rate)
15.8%
per year from 2007 to 2026, per share 15.9%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2021 | since 2016 | since 2007 | |
|---|---|---|---|
| Revenue | 8.3% | 7.0% | 7.0% |
| Revenue per share | 7.1% | 6.4% | 7.0% |
| Earnings | −8.6% | −0.2% | 11.8% |
| Earnings per share | −9.7% | −0.8% | 11.9% |
| Free cash flow | 14.8% | 10.8% | 15.8% |
| Free cash flow per share | 13.5% | 10.1% | 15.9% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2007 | $1.19B | $54.85M | $60.48M |
| 2008 | $1.25B | $105.99M | $103.91M |
| 2009 | $1.31B | $130.89M | $209.45M |
| 2010 | $1.41B | $184.25M | $216.86M |
| 2011 | $1.51B | $269.64M | $289.8M |
| 2012 | $1.63B | $325.22M | $342.57M |
| 2013 | $1.72B | $401.86M | $399.64M |
| 2014 | $1.84B | $354.28M | $387.78M |
| 2015 | $2.06B | $133.26M | $403.19M |
| 2016 | $2.18B | $465.9M | $352.65M |
| 2017 | $2.3B | $562.84M | $380.37M |
| 2018 | $2.44B | $569.96M | $547.28M |
| 2019 | $2.66B | $574.11M | $551.57M |
| 2020 | $2.75B | $622.13M | $567.44M |
| 2021 | $2.88B | $715.22M | $492.73M |
| 2022 | $3.35B | $697.58M | $587.6M |
| 2023 | $3.63B | $709M | $442.48M |
| 2024 | $4.01B | $748.87M | $237.17M |
| 2025 | $4.13B | $538.97M | $791.42M |
| 2026 | $4.29B | $455.67M | $981.3M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 30 Sep 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = DKK 6.7461)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral since 12 Nov 2026, previously Strong
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.